Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Payables (2016 - 2025)

Historic Payables for Macrogenics (MGNX) over the last 14 years, with Q3 2025 value amounting to $5.9 million.

  • Macrogenics' Payables fell 1017.69% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year decrease of 1017.69%. This contributed to the annual value of $5.0 million for FY2024, which is 2219.46% down from last year.
  • As of Q3 2025, Macrogenics' Payables stood at $5.9 million, which was down 1017.69% from $4.7 million recorded in Q2 2025.
  • Macrogenics' Payables' 5-year high stood at $15.5 million during Q4 2021, with a 5-year trough of $2.6 million in Q2 2022.
  • For the 5-year period, Macrogenics' Payables averaged around $6.3 million, with its median value being $5.2 million (2024).
  • Per our database at Business Quant, Macrogenics' Payables soared by 42893.66% in 2021 and then plummeted by 7342.64% in 2022.
  • Quarter analysis of 5 years shows Macrogenics' Payables stood at $15.5 million in 2021, then plummeted by 68.39% to $4.9 million in 2022, then skyrocketed by 31.52% to $6.4 million in 2023, then fell by 22.19% to $5.0 million in 2024, then grew by 18.49% to $5.9 million in 2025.
  • Its Payables stands at $5.9 million for Q3 2025, versus $4.7 million for Q2 2025 and $6.6 million for Q1 2025.